“…The primary mouse MAbs HMB-45 (lot 0024b; DAKO A/S, Copenhagen, Denmark; diluted 1 : 200) to immature melanosomes that labels more than 90% of primary and metastatic uveal melanomas (30)(31)(32), MAb CY-90 (lot 49F-4815; Sigma Chemical Co.; 1 : 3000) to cytokeratin 18 that is expressed by adenocarcinomas, but can also be found in a minority of cells in uveal melanomas (26), MAb Vim 3B4 (lot 114544324-01; BoehringerMannheim GmbH, Mannheim, Germany; diluted 1 : 50) to vimentin that labels uveal melanomas (26) but may also label cells in some carcinomas, and MAb E29 (lot 078; DAKO; diluted 1 : 25) to epithelial membrane antigen produced by adenocarcinomas but not by melanomas (33) were commercially obtained. A tumor was accepted as a melanoma if it reacted for HMB-45, vimentin, or both, but not for cytokeratin 18 and epithelial membrane antigen, and as a carcinoma when the antigenic profile was the opposite.…”